GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford them.
Around half a million Australians are now using GLP-1 medicines. Nearly half access these medicines privately, paying between A$200 and $700 a month out of pocket.
